A detailed history of Vanguard Group Inc transactions in Dare Bioscience, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,358,215 shares of DARE stock, worth $14 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,358,215
Previous 3,450,328 2.67%
Holding current value
$14 Million
Previous $1.69 Million 32.49%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$0.28 - $0.61 $25,791 - $56,188
-92,113 Reduced 2.67%
3,358,215 $1.14 Million
Q1 2024

May 10, 2024

BUY
$0.31 - $0.57 $531 - $978
1,716 Added 0.05%
3,450,328 $1.69 Million
Q4 2023

Feb 14, 2024

BUY
$0.29 - $0.53 $1,141 - $2,086
3,937 Added 0.11%
3,448,612 $1.07 Million
Q2 2023

Aug 14, 2023

SELL
$0.91 - $1.05 $14,145 - $16,322
-15,545 Reduced 0.45%
3,444,675 $3.13 Million
Q1 2023

May 15, 2023

SELL
$0.87 - $1.36 $65,450 - $102,312
-75,230 Reduced 2.13%
3,460,220 $3.6 Million
Q4 2022

Feb 10, 2023

BUY
$0.82 - $12.6 $1,547 - $23,776
1,887 Added 0.05%
3,535,450 $2.93 Million
Q3 2022

Nov 14, 2022

BUY
$1.04 - $12.48 $31,510 - $378,131
30,299 Added 0.86%
3,533,563 $3.53 Million
Q2 2022

Aug 12, 2022

BUY
$0.94 - $1.76 $47,228 - $88,427
50,243 Added 1.46%
3,503,264 $4.31 Million
Q1 2022

May 13, 2022

BUY
$1.42 - $2.09 $563,694 - $829,663
396,968 Added 12.99%
3,453,021 $5.15 Million
Q4 2021

Feb 14, 2022

BUY
$1.42 - $2.13 $1.26 Million - $1.9 Million
889,744 Added 41.07%
3,056,053 $6.11 Million
Q3 2021

Nov 12, 2021

BUY
$1.42 - $2.0 $319,572 - $450,102
225,051 Added 11.59%
2,166,309 $3.62 Million
Q2 2021

Aug 13, 2021

BUY
$1.21 - $1.89 $2.35 Million - $3.67 Million
1,941,258 New
1,941,258 $3.67 Million

Others Institutions Holding DARE

About Dare Bioscience, Inc.


  • Ticker DARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,820,896
  • Market Cap $353M
  • Description
  • Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription pr...
More about DARE
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.